Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 19/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15212394 | 0.88 | ALPL (0.80) | ALPLMAPTALOX12 | |
| SCHEMBL15212032 | 0.88 | ALPL (0.73) | ALPL | |
| SCHEMBL16376112 | 0.86 | ALPL (0.63) | ALPL | |
| SCHEMBL16375017 | 0.84 | ALPL (0.78) | ALPL | |
| SCHEMBL18296939 | 0.83 | ALPL (0.75) | ALPL | |
| SCHEMBL16375245 | 0.83 | ALPL (0.69) | ALPL | |
| SCHEMBL16376113 | 0.82 | ALPL (0.76) | ALPL | |
| SCHEMBL15211794 | 0.78 | ALPL (0.81) | ALPLMAPTALOX12 | |
| SCHEMBL16375241 | 0.78 | ALPL (0.77) | ALPL | |
| SCHEMBL15211873 | 0.78 | ALPL (1.00) | ALPLMAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355479-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-12-08 | — | — | US | disclosed |
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885MAPT 2764/4885ALOX12 4061/4885 |
| US-20160355479-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885MAPT 2764/4885ALOX12 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.